BioNexus Gene Lab Corp Common stock (NASDAQ:BGLC) — Stock Price
BioNexus Gene Lab Corp Common stock (NASDAQ:BGLC) is currently trading at $1.56 USD, down 4.88% today. Over the past 52 weeks, shares have ranged between $1.32 and $6.00. This page tracks BioNexus Gene Lab Corp Common stock's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see BGLC market cap overview.
BioNexus Gene Lab Corp Common stock (BGLC) Stock Price Chart — Daily History & Trading Volume
The chart below tracks BioNexus Gene Lab Corp Common stock's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
BioNexus Gene Lab Corp Common stock Income Statement — Revenue, Profit & Earnings by Year
BioNexus Gene Lab Corp Common stock's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $9.51 Million | $9.77 Million | $10.93 Million | $13.36 Million | $11.39 Million |
| Cost of Revenue | $8.22 Million | $8.44 Million | $9.67 Million | $11.17 Million | $9.67 Million |
| Gross Profit | $1.29 Million | $1.33 Million | $1.26 Million | $2.19 Million | $1.72 Million |
| Research & Development | $47.51K | $54.98K | — | — | — |
| SG&A | $1.97 Million | $2.44 Million | $1.73 Million | $1.20 Million | $1.33 Million |
| Total Operating Expenses | $2.86 Million | $3.92 Million | $1.55 Million | $1.14 Million | $446.00K |
| Operating Income | $-1.57 Million | $-2.59 Million | $-291.18K | $1.06 Million | $1.27 Million |
| EBITDA | $-1.42 Million | $-2.49 Million | $-185.76K | $1.16 Million | $1.38 Million |
| EBIT | $-1.57 Million | $-2.59 Million | $-291.18K | $1.06 Million | $1.27 Million |
| Interest Expense | $21.15K | $13.93K | $12.48K | $12.97K | $11.31K |
| Income Before Tax | $-1.59 Million | $-2.61 Million | $-303.66K | $1.04 Million | $1.26 Million |
| Income Tax Expense | $3.49K | $21.53K | $52.31K | $291.28K | $168.41K |
| Net Income | $-1.60 Million | $-2.63 Million | $-355.97K | $751.57K | $1.09 Million |
BioNexus Gene Lab Corp Common stock Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes BioNexus Gene Lab Corp Common stock's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | $10.43 Million | $11.40 Million | $8.74 Million | $9.57 Million | $10.12 Million |
| Total Current Assets | $7.43 Million | $8.05 Million | $6.02 Million | $7.08 Million | $7.99 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $2.79 Million | $3.31 Million | $1.51 Million | $1.55 Million | $2.09 Million |
| Net Receivables | $1.58 Million | $857.26K | $2.90 Million | $3.36 Million | $4.00 Million |
| Inventory | $1.39 Million | $1.14 Million | $977.81K | $1.52 Million | $1.18 Million |
| Property, Plant & Equipment | — | — | — | $1.63 Million | $1.79 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $2.11 Million | $1.74 Million | $2.08 Million | $2.39 Million | $3.45 Million |
| Total Current Liabilities | $1.95 Million | $1.63 Million | $2.00 Million | $2.33 Million | $3.37 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-4.17 Million | $-5.78 Million | $-2.06 Million | $-2.05 Million | $-2.66 Million |
| Total Stockholder Equity | $8.32 Million | $9.66 Million | $6.67 Million | $7.18 Million | $6.66 Million |
| Retained Earnings | $-3.44 Million | $-1.84 Million | $1.16 Million | $1.51 Million | $760.79K |
BioNexus Gene Lab Corp Common stock Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how BioNexus Gene Lab Corp Common stock generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-2.23 Million | $-1.76 Million | $544.03K | $9.16K | $552.68K |
| Capital Expenditures | $226.99K | $149.40K | $54.17K | $3.16K | $421.62K |
| Free Cash Flow | $-2.46 Million | $-1.91 Million | $489.86K | $6.00K | $131.06K |
| Investing Cash Flow | $418.20K | $-1.86 Million | $-450.50K | $-490.57K | $1.32 Million |
| Financing Cash Flow | $144.97K | $6.27 Million | $115.96K | $-28.22K | $-4.95K |
| Dividends Paid | $68.13K | $115.38K | $0.12 | $22.04K | $6.31K |
| Stock-Based Compensation | — | $511.74K | $0.00 | — | — |
| Depreciation | $153.14K | $108.42K | $105.42K | $108.22K | $101.60K |
| Change in Cash | $-1.63 Million | $3.81 Million | $-5.05K | $-663.77K | $1.93 Million |
BioNexus Gene Lab Corp Common stock Earnings History — EPS Actual vs. Analyst Estimates
Track BioNexus Gene Lab Corp Common stock's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 14, 2025 | -0.40 | — | — |
| Aug 18, 2025 | -0.34 | 0.00 | — |
| Apr 15, 2025 | -0.19 | — | — |
| Dec 31, 2024 | -0.19 | — | — |
| Sep 30, 2024 | -0.75 | — | — |
| Jun 30, 2024 | 0.11 | — | — |
| Mar 31, 2024 | -0.06 | — | — |
| Dec 31, 2023 | 0.17 | — | — |